Andrew Callos

Andrew joined us as Executive Vice President, Chief Commercial Officer in March 2021.

Andrew has a deep biopharma background which includes well over 20 years at Pfizer and Wyeth Pharmaceuticals, including roles of increasing responsibility overseeing US and International pharmaceutical franchises. Most recently Andrew served as Regional President and General Manager North America, Upjohn Business Unit at Pfizer. Prior to this role and during his 11+ years at Pfizer, he held several leadership positions including Vice President U.S. Cardiology & Metabolic Marketing where he led the commercialization of Eliquis in the U.S., Vice President and Head of Inflammation Marketing Europe and Vice President Global Commercial Development Rare Disease. Prior to Pfizer, Andrew spent over 10 years at Wyeth Pharmaceuticals in various roles within Business Planning & Analysis, ultimately serving as AVP Marketing across several products. Andrew started the first 7 years of his career as a Consulting Manager at Accenture.

Andrew received a B.S. in Commerce and Engineering from Drexel University.